Hereditary hemorrhagic telangiectasia
MONDO:0019180A disorder of angiogenesis leading to arteriovenous dilatations: cutaneo-mucosal hemorrhagic telangiectasias and visceral shunting.
Also known as: HHT, Osler-Weber-Rendu disease, Rendu-Osler disease, Rendu-Osler-Weber disease, hereditary hemorrhagic telangiectasia, telangiectasia, hereditary Hemorrahagic, of Rendu, Osler, telangiectasia, hereditary hemorrhagic
39 clinical trials for this condition and its sub-types, 34 tagged with Hereditary hemorrhagic telangiectasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hereditary hemorrhagic telangiectasia
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThis study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will recei…
Phase 1/2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Cancer drug shows promise for rare bleeding disorder
Disease control OngoingThis phase 2 trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal blood vessels that bleed easily. The study involves 33 adul…
Phase 2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
HHT drug trial pulled before it even started
Disease control CancelledThis was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn bef…
Phase 1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
Disease control OngoingThis study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researc…
Phase 2/3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to stop nosebleeds in rare genetic disorder
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and sever…
Phase 1/2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug tame rare bleeding Disorder's heart complications?
Disease control By invitation onlyThis study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused OngoingThis study is creating a registry of people with Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessels and frequent nosebleeds. Researchers will collect health information from about 1,000 adults over many years to see how the disease ch…
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC